All cancer patients in drug trial appear to be cured for ‘first time in history’

‘This is the first time this has happened’: All 12 patients involved in US study entered remission after taking dostarlimab over a six-month period

Samuel Lovett
Senior News Correspondent
Wednesday 08 June 2022 12:03
Comments

Scientists have said the promising results will need to be repeated

An experimental cancer drug appears to have cured every single patient in a small clinical trial conducted in the US.

The 12 patients, all of whom had been diagnosed with rectal cancer, entered remission after taking dostarlimab over a six-month period, according to a study published in The New England Journal of Medicine.

“This is the first time this has happened in the history of cancer,” Dr Luis Diaz, one of the lead authors of the paper and an oncologist at the Memorial Sloan Kettering Cancer Centre in New York, told The New York Times.

The patients also experienced no significant side effects during the course of their treatment, though it’s believed not enough people were involved in the study to highlight the different adverse reactions that can be caused by the drug.

Although excited by the research, scientists have said the promising results will need to be repeated, and cautioned against concluding that the cancer had been eradicated permanently.

Dostarlimab is an immunotherapy drug used in the treatment of endometrial cancer, but this was the first clinical investigation into whether it could be effective against rectal cancer tumours.

The drug works by unmasking cancer cells, allowing the immune system to identify and destroy them.

For the research, the 12 patients received dostarlimab every three weeks for six months. This treatment was to be followed by standard chemoradiotherapy and surgery.

However, six months after the patients stopped taking the medication, their cancer had vanished, being undetectable by physical exam, endoscopy, PET or MRI scans.

Two years on from the study, the patients appear to remain cancer-free, and none of the participants in the trial have yet received chemoradiotherapy or undergone surgery.

Dr Hanna Sanoff, of the University of North Carolina, who was not involved in the research, said the study was “small but compelling”.

“These results are cause for great optimism,” she wrote in an editorial accompanying the paper, adding that the research had “provided what may be an early glimpse of a revolutionary treatment shift”.

However, she cautioned that “such an approach cannot yet supplant our current curative treatment approach”, adding that it remains unclear whether the patients are cured.

“Very little is known about the duration of time needed to find out whether a clinical complete response to dostarlimab equates to cure,” Dr Sanoff wrote.

In separate comments, Dr Sanoff explained that dostarlimab is a type of drug called an immune checkpoint inhibitor.

“These are immunotherapy medicines that work not by directly attacking the cancer itself, but actually getting a person’s immune system to essentially do the work,” she said.

“And these are drugs that have been around in melanoma and other cancers for quite a while, but really have not been part of the routine care of colorectal cancers until fairly recently.”

All of the 12 patients in the study had tumours with a genetic mutation known as mismatch repair deficiency (MMRd), which is seen in a subset of approximately 5 to 10 per cent of patients with rectal cancer.

Patients with such tumours tend to be less responsive to chemotherapy and radiation treatments, which increases the need for surgical removal of their tumours.

However, MMRd mutations can also make cancer cells more vulnerable to the body’s immune response, especially when it’s bolstered by an immunotherapy agent – in this case, dostarlimab.

Dr Kimmie Ng, a colorectal cancer expert at Harvard Medical School, told The New York Times the results were “remarkable” and “unprecedented”, but said they would need to be replicated in order to establish their significance.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in